this study. "But given these findings, it is appropriate
for pediatricians to discuss with families the risks and unclear
benefits of daily preventive antibiotic treatment after a child has
had a first UTI."
UTIs are common in children. In fact, of all the children born
in one year, 70,000 to 180,000 will have a UTI by age six.
The American Academy of Pediatrics (AAP) practice guideline for
management of children after a first UTI recommends an imaging
study to evaluate the presence and degree of vesicoureteral reflux
(VUR), a condition found in approximately 30 to 40 percent of
children who have had a UTI. If the child has VUR, daily antibiotic
treatment is recommended in an attempt to prevent recurrent
UTIs.
Vesicoureteral reflux (VUR) occurs when urine in the bladder
flows back into the ureters or kidneys during urination. It is
thought that a child who has VUR is at risk for developing
recurrent kidney infections, which, over time, can cause damage to
the kidneys. However, Dr. Conway summarized, "The majority of
children have lower grade VUR and this lower grade VUR was not
associated with an increased risk of recurrent UTI in our
study."
Grants from the National Institutes of Health, the Robert Wood
Johnson Foundation Clinical Scholars Training Program and the
University of Pennsylvania Center for Education and Research on
Therapeutics supported this study.
Dr. Conway and Dr. Keren's coauthors were Avital Cnaan, Ph.D.;
Theoklis Zaoutis, M.D., M.S.C.E.; Brandon V. Henry; and Robert W.
Grundmeier, M.D., all of The Children's Hospital of Philadelphia
and the University of Pennsylvania School of Medicine.
About The Children's Hospital of Philadelphia: The Children's
Hospital of Philadelphia was founded in 1855 as the nation's first
pediatric hospital. Through its long-standing commitment to
providing exceptional patient care, training new generations of
pediatric healthcare professionals and pioneering major research
initia
'"/>
Page: 1 2 3 Related medicine technology :1.
Targanta Reports Improved Ability of Oritavancin to Stop Bacteria
Growth In Vitro Compared With Other Glycopeptide Antibiotics2.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery3.
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery4.
Peer Reviewed Journal Article Indicates Repros Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
Breast Cancer5.
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions6.
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of
Blindness in Premature Infants7.
Accera, Inc. Announces Open-Label Data from Phase II Study in
Alzheimers Disease at International Conference on Prevention of
Dementia8.
At the 2007 Alzheimers Association International Conference on the
Prevention of Dementia - Neurochems U.S. Principal Investigator
Presents Update on Tramiprosate (Alzhemed)9.
Frova Phase III Study Data Demonstrates That Short-Term Prevention
Treatment Reduces Frequency and Severity of Menstrual Migraine10.
New Research Confirms the Benefit of Extended-Release Dipyridamole
Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk
Patients11.
Investigation Findings, Corroborated by Empirical Evidence of the
Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine
for Hundreds of Years, Support the Use of Schisandrin B in the
Prevention and Treatment of IHD